Alacepril

The proliferation of severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) and the persistent corona-virus disease 2019 (COVID-19) pandemic emphasize the necessity for novel treatments.Among the diverse pharmacol. agents under scrutiny, cannabinoids have garnered attention for their potential antiviral properties.This study utilizes mol. docking and simulation techniques to explore the interaction between cannabinoids drugs and essential SARS-CoV-2 viral proteins, aiming to identify potential therapeutic effects.The results suggest favorable binding energies between certain cannabinoids drugs and viral proteins, especially at the active sites of the spike protein.Our computational findings reveal that the ligands Cannabiscitrin and Cannabisin D exhibit the highest binding affinity (approx. -9.11 and -8.84 kcal/mol, resp.) toward the SARS-CoV-2 receptor, while Alacepril displays the lowest affinity (-6.32 kcal/mol) for the SARS-CoV-2 receptor.The findings suggest a potential inhibitory effect of cannabinoid drugs on both viral entry and replication.Furthermore, simulations demonstrate cannabinoid binding to the CB2 receptor, suggesting potential immunomodulatory roles in SARS-CoV-2 infection.This research underscores the promise of cannabinoids as SARS-CoV-2 therapeutic agents, necessitating further validation and clin. exploration.